A resurrection of 7-MEOTA: A comparison with tacrine

Current Alzheimer Research

Volumn 10, Issue 8, 2013, Pages 893-906

  Soukup, Ondrej ^a,b   Jun, Daniel ^a,b   Zdarova Karasova, Jana ^a,b   Patocka, Jiri ^d   Musilek, Kamil ^a,c   Korabecny, Jan ^b   Krusek, Jan ^f   Kaniakova, Martina ^f   Sepsova, Vendula ^b   Mandikova, Jana ^e   Trejtnar, Frantisek ^e   Pohanka, Miroslav ^b   Drtinova, Lucie ^b   Pavlik, Michal ^b   Tobin, Gunnar ^g   Kuca, Kamil ^a,b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^d UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

7 Methoxytacrine; Acetylcholinesterase inhibitor; Alzheimer's disease drug; Cholinergic hypothesis; Pharmacological profile; Tacrine

Indexed keywords

7 METHOXYTACRINE; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; TACRINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GENETIC ALGORITHM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; LD 50; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CHOLINESTERASE INHIBITORS; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; TACRINE;

EID: 84888041417     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310080011     Document Type: Article

References (82)

1. Silvestrelli G, Lanari A, Parnetti L, Tomassoni D, Amenta F. Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology. Mech Ageing Dev 127: 148-157 (2006).
2. Alzheimer's disease facts and figures. Alzheimer's and Dementia 7: 208-244 (2011).
3. Bartus RT, Dean RL, Beer B, Lippa AS. The Cholinergic Hypothesis of Geriatric Memory Dysfunction. Science 217: 408-417 (1982).
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews (2006).
5. Sugimoto H. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chem Biol Interact 175: 204-208 (2008).
6. Shah RS, Lee H-G, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Biomed & Pharmacother 62: 199-207 (2008).
7. Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 Muscarinic Agonists as Potential Disease-Modifying Agents in Alzheimer's Disease: Rationale and Perspectives. Ann NY Acad Sci 920: 315-320 (2000).
8. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig Jr, Albuquerque EX, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 49: 279-288 (2001).
9. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Bio Med 23: 134-147 (1997).
10. Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 122: 1961-1969 (2001).
11. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51: 2326-2326 (2008).
12. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 28: 774-751 (1994).
13. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimers-Disease. JAMA-J Am Med Assoc 271: 992-998 (1994).
14. Zeiger E, Erexson G, Mortelmans K, Thilagar A. Genetic toxicity studies of 1, 2, 3, 4-tetrahydro-9-acridinamine (tacrine). Mutat Res Genet Toxicol Environ Mutagen 393: 189-197 (1997).
15. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, Asher SW et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 268: 2523 (1992).
16. Patocka J, Bielavsky J, Fusek J. Advances in Synthesis of Tacrine Derivatives as Potential-Drugs for Treatment of Alzheimers-Disease. Homeost Health Dis 35: 299-301 (1994).
17. Bajgar J, Bisso GM, Michalek H. Differential Inhibition of Rat-Brain Acetylcholinesterase Molecular-Forms by 7-Methoxytacrine in-Vitro. Toxicol Lett 80: 109-114 (1995).
18. Bajgar J, Fusek J, Patocka J, Hrdina V. Invivo Kinetics of Blood Cholinesterase Inhibition by "9-Amino-1, 2, 3, 4-Tetrahydroacridine, Its 7-Methoxy Derivative and Physostigmine in Rats. Physiologia Bohemoslovaca 28: 31-34 (1979).
19. Patocka J, Bajgar J, Bielavsky J, Fusek J. Kinetics of Inhibition of Cholinesterases by 1, 2, 3, 4-Tetrahydro-9-Aminoacridine Invitro. Collect Czech Chem Commun 41: 816-824 (1976).
20. Giacobini E. Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease. Neurochem Res 28: 515-522 LA-English (2003).
21. Greig NH, Utsuki T, Yu Q-s, Zhu X, Holloway HW, Perry T, Lee B, et al. A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase. Curr Med Res Opin 17: 159-165 (2001).
22. Adem A. Putative Mechanisms of Action of Tacrine in Alzheimers-Disease. Acta Neurol Scand 85: 69-74 (1992).
23. Adem A, Mohammed AK, Winblad B. Multiple Effects of Tetrahydroaminoacridine on the Cholinergic System-Biochemical and Behavioral-Aspects. J. Neural Transm.-Park Dis Dement Sect 2: 113-128 (1990).
24. Bajgar J, Skopec F, Herink J, Patocka J, Kvetina J. Effect of 7-methoxytacrine and L-carnitine on the activity of choline acetyltransferase. Gen Physiol Biophys 18: 3-6 (1999).
25. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu Q-s, Utsuki T, Giordano T, et al. The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-Beta Peptide Levels in Cell Culture and Mice. J Pharmacol Exp Therap 320 386-396 (2007).
26. Lahiri DK, Farlow MR, Sambamurti K. The secretion of amyloid Beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Mol Brain Res 62: 131-140 (1998).
27. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 37: 777-787 (1994).
28. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine Lowers A and Increases sAPPBeta Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons. PLoS ONE 6: e21954 EP-(2011).
29. Dolezal V, Tucek S. Positive and Negative Effects of Tacrine (Tetrahydroaminoacridine) and Methoxytacrine on the Metabolism of Acetylcholine in Brain Cortical Prisms Incubated under Resting Conditions. J Neurochem 56: 1207-1215 (1991).
30. Tucek S, Dolezal V. Negative Effects of Tacrine (Tetrahydroaminoacridine) and Methoxytacrine on the Metabolism of Acetylcholine in Brain-Slices Incubated under Conditions Stimulating Neurotransmitter Release. J Neurochem 56: 1216-1221 (1991).
31. Herink J, Bajgar J, Koupilova N. Different Inhibition of Brain Acetylcholinesterase Activity Following Intramuscular and Intracerebroventricular Administration of 7-Methoxytacrine. Behav Pharmacol 9: S43 (1998).
32. Dejmek L. 7-MEOTA. Drug Future 15: 126-129 (1990).
33. Patocka J, Bielavsky J. Biotransformation of the anticholinesterase agent, 9-amino-7-methoxy-1, 2, 3, 4-tetrahydroacridine. Cesk Farm 40: 130-132 (1991).
34. Patocka J, Jun D, Kuca K. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab 9: 332-335 (2008).
35. Patocka J, Koupilova N, Herink J, Fusek J, Bajgar J, Cabal J. Preclinical comparison of tacrine nad 7-methoxytacrine. Homeostasis 38: 24-25 (1997).
36. Filip V, Vachek J, Albrecht V, Dvorak I, Dvorakova J, Fusek J, et al. Pharmacokinetics and Tolerance of 7-Methoxytacrine Following the Single Dose Administration in Healthy-Volunteers. Int J Clin Pharmacol Ther 29: 431-436 (1991).
37. Korabecny J, Holas O, Musilek K, Pohanka M, Opletalova V, Dohnal V, et al. Synthesis and In vitro Evaluation of New Tacrine Derivates-Bis-Alkylene Linked 7-MEOTA. Lett Organ Chem 7: 327-331 (2010).
38. Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Marek J, et al. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett 20: 6093-5 (2010).
39. Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Opletalova V, et al. Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1, 2, 3, 4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules 15: 8804-12 (2010).
40. Kozurkova M, Hamulakova S, Gazova Z, Paulikova H, Kristian P. Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties. Pharmaceuticals 4: 382-418 (2011).
41. Pohanka M, Jun D, Kuca K. Improvement of acetylcholinesterasebased assay for organophosphates in way of identification by reactivators. Talanta 77: 451-454 (2008).
42. Karasova JZ, Bajgar J, Jun D, Pavlikova R, Kuca K. Time-Course Changes of Acetylcholinesterase Activity in Blood and Some Tissues in Rats After Intoxication by Russian VX. Neurotox Res 16: 356-360 (2009).
43. Giacobini E, Holmstedt B. Cholinesterase Content of Certain Regions of the Spinal Cord as Judged by Histochemical and Cartesian Diver Technique. Acta Physiol Scand 42: 12-27 (1958).
44. Kuca K, Cabal J, Jung YS, Musilek K, Soukup O, Jun D, et al. Reactivation of Human Brain Homogenate Cholinesterases Inhibited by Tabun using Newly Developed Oximes K117 and K127. Basic Clin Pharmacol Toxicol 105: 207-210 (2009).
45. Kuca K, Jun D. Reactivation of sarin-inhibited pig brain acetylcholinesterase using oxime antidotes. J Med Toxicol 2: 141-6 (2006).
46. Kamenicek J, Herichy P, Kuca K, Jun D, Olsovsky M. Planar Ni(II) 1, 2-dithiolenes involving bidentate N-donor ligands. J Coord Chem 61: 3525-3533 (2008).
47. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662 (1998).
48. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera-A visualization system for exploratory research and analysis. J Comput Chem 25: 1605-1612 (2004).
49. Pohanka M, Sobotka J, Jilkova M, Stetina R. Oxidative stress after sulfur mustard intoxication and its reduction by melatonin: efficacy of antioxidant therapy during serious intoxication. Drug Chem Toxicol 34: 85-91 (2011).
50. Soukup O, Kumar UK, Proska J, Bratova L, Adem A, Jun D, et al. The effect of oxime reactivators on muscarinic receptors: Functional and binding examinations. Environ Toxicol and Pharmacol 31: 364-370 (2011).
51. Mayer ML, Vyklicky L, Clements J. Regulation of Nmda Receptor Desensitization in Mouse Hippocampal-Neurons by Glycine. Nature 338: 425-427 (1989).
52. Dittert I, Vlachova V, Knotkova H, Vitaskova Z, Vyklicky L, Kress M, et al. A technique for fast application of heated solutions of different composition to cultured neurones. J Neurosci Method 82: 195-201 (1998).
53. Musilek K, Komloova M, Zavadova V, Holas O, Hrabinova M, Pohanka M, et al. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. Bioor Med Chem Lett 20: 1763-1766 (2010).
54. Harel M, Schalk I, Ehretsabatier L, Bouet F, Goeldner M, Hirth C, et al. Quaternary Ligand-Binding to Aromatic Residues in the Active-Site Gorge of Acetylcholinesterase. Proc Natl Acad Sci USA 90: 9031-9035 (1993).
55. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278: 41141-41147 (2003).
56. Quesenberry KE, W. CJ. In: Ferrets, Rabbits and Rodents Clinical Medicine and Surgery: Saunders (2004).
57. Valenti P, Rampa A, Bisi A, Andrisano V, Cavrini V, Fin L, et al. Acetylcholinesterase inhibition by tacrine analogues. Bioorg Med Chem Lett 7: 2599-2602 (1997).
58. del Monte-Millán M, García-Palomero E, Valenzuela R, Usán P, de Austria C, Munoz RP, et al. Dual binding site acetylcholinesterase inhibitors. J Mol Neurosci 30: 85-87 (2006).
59. Bornstein JJ, Eckroat TJ, Houghton JL, Jones CK, Green KD, Garneau-Tsodikova S. Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase. Med Chem Commun. 2: 406-412 (2011).
60. Valenti P, Rampa A, Bisi A, Andrisano V, Cavrini V, Fin L, et al. Acetylcholinesterase inhibition by tacrine analogues. Bioorg Med Chem Lett 7: 2599-2602 (1997).
61. Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M. Design and synthesis of tacrine ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg Med Chem Lett 18: 2905-2909 (2008).
62. Costagli C, Galli A. Inhibition of Cholinesterase-associated Aryl Acylamidase Activity by Anticholinesterase Agents: Focus on Drugs Potentially Effective in Alzheimer's Disease. Biochem Pharmacol 55: 1733-1737 (1998).
63. Patocka J. 9-amino-7-methoxy-1, 2, 3, 4-tetrahydroakridin, nova latka s neprimym cholinomimetickym ucinkem (in Czech). Ceskoslovenska Farmacie (in czech) 39: 29-32 (1990).
64. Pohanka M, Kuca K, Kassa J. New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine. Neuroendocrinol Lett 29: 755-758 (2008).
65. Osseni RA, Debbasch C, Christen MO, Rat P, Warnet JM. Tacrineinduced reactive oxygen species in a human liver cell line: The role of anethole dithiolethione as a scavenger. Toxicol in vitro 13: 683-688 (1999).
66. Galisteo M, Rissel M, Sergent O, Chevanne M, Cillard J, Guillouzo A, et al. Hepatotoxicity of tacrine: Occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Therap 294: 160-167 (2000).
67. Bhat SH, Azmi AS, Hanif S, Hadi SM. Ascorbic acid mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: A putative mechanism for anticancer properties. Int J Biochem Cell Biol 38: 2074-2081 (2006).
68. Pohanka M. Alzheimer's disease and related neurodegenerative disorders: implication and counteracting of melatonin. J Appl Biomed (2011).
69. Fisher A, Heldman E, Gurwitz D, Harink R, Karton Y, Meshulam H, et al. M1 Agonists for the Treatment of Alzheimer's Disease. Ann NY Acad Sci 777: 189-196 (1996).
70. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48: 913-8 (2000).
71. Whitehouse PJ, Martino AM, Marcus KA, Zweig RM, Singer HS, Price DL, et al. Reductions in Acetylcholine and Nicotine Binding in Several Degenerative Diseases. Arch Neurol 45: 722-724 (1988).
72. Rusted JM, Newhouse PA, Levin ED. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav Brain Res 113: 121-129 (2000).
73. Canti C, Bodas E, Marsal J, Solsona C. Tacrine and physostigmine block nicotinic receptors in Xenopus oocytes injected with Torpedo electroplaque membranes. Eur J Pharmacol 363: 197-202 (1998).
74. Cheffer A, Ulrich H. Inhibition Mechanism of Rat alpha(3)beta(4) Nicotinic Acetylcholine Receptor by the Alzheimer Therapeutic Tacrine. Biochemistry 50: 1763-1770.
75. Prince RJ, Pennington RA, Sine SM. Mechanism of Tacrine Block at Adult Human Muscle Nicotinic Acetylcholine Receptors. J Gen Physiol 120: 369-393 (2002).
76. Newhouse PA, Potter A, Corwin J, Lenox R. Acute Nicotinic Blockade Produces Cognitive Impairment in Normal Humans. Psychopharmacology 108: 480-484 (1992).
77. Nilsson L, Adem A, Hardy J, Winblad B, and Nordberg A. Do Tetrahydroaminoacridine (Tha) and Physostigmine Restore Acetylcholine-Release in Alzheimer Brains Via Nicotinic Receptors. J Neural Transm 70: 357-368 (1987).
78. Beani L, Bianchi C, Nilsson L, Nordberg A, Romanelli L, Sivilotti L. The Effect of Nicotine and Cytisine on H-3-Acetylcholine Release from Cortical Slices of Guinea-Pig Brain. Naunyn-Schmiedebergs Arch Pharmacol 331: 293-296 (1985).
79. Lazareno S and Birdsall NJM. Pharmacological Characterization of Acetylcholine-Stimulated S-35 Gtp-Gamma-S Binding Mediated by Human Muscarinic M1-M4 Receptors-Antagonist Studies. Br J Pharmacol 109: 1120-1127 (1993).
80. Zhang X, Tian JY, Svensson AL, Gong ZH, Meyerson B, Nordberg A. Chronic treatments with tacrine and (-)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat. J Neural Transm 109: 377-392 (2002).
81. Lou G, Montgomery PR, Sitar DS. Bioavailability and Pharmacokinetic Disposition of Tacrine in Elderly Patients with Alzheimer's Disease. J Psych Neurosci 21: 334-339 (1996).
82. Ahlin A, Adem A, Junthe T, Ohman G, Nyback H. Pharmacokinetics of Tetrahydroaminoacridine-Relations to Clinical and Biochemical Effects in Alzheimer Patients. Int Clin Psychopharmacol 7: 29-36 (1992).